Frei A, Palmer A J, Burnier M, Hess B
Gesundheitsökonomische Studien und Beratung, Pratteln.
Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. doi: 10.1024/0369-8394.95.11.401.
The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy). The objective of this study was to investigate the long-term health economic consequences of this treatment strategy in a Swiss health care setting. This analysis used a Markov model to simulate the progression of nephropathy, life-years and treatment costs over ten years for each of the three treatment options. In additon, sensitivity analyses were performed. Treatment with irbesartan will save CHF 22681/patient as compared with amlodipine and CHF 13847 as compared with standard therapy.
厄贝沙坦治疗糖尿病肾病试验（IDNT）表明，与氨氯地平和安慰剂（抗高血压标准疗法）相比，用厄贝沙坦治疗2型糖尿病、高血压和肾病患者可使血清肌酐翻倍、终末期肾病或死亡的复合终点相对降低20%。本研究的目的是在瑞士医疗环境中调查这种治疗策略的长期健康经济后果。该分析使用马尔可夫模型来模拟三种治疗方案中每种方案在十年内肾病的进展、生命年和治疗成本。此外，还进行了敏感性分析。与氨氯地平相比，厄贝沙坦治疗每位患者可节省22681瑞士法郎，与标准疗法相比可节省13847瑞士法郎。
